BeiGene, a Hong Kong and Nasdaq-listed global, biotechnology company focused on developing affordable medicines, has priced an IPO on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (SSE). According to IFR, the retail tranche was 3,531 times covered. The offering was priced at Rmb192.60 per ordinary share, which raises around…
Home Healthcare Markets International Business China: BeiGene prices hugely popular IPO on Star market of Shanghai Exchange